Novartis beats Q3 estimates but investors balk at plans to delay Alcon exit
admin 24th October 2017 Uncategorised 0Novartis’ stock dipped 2% after the company beat expectations for both sales and earnings in the third quarter. The culprit is likely Alcon, Novartis’ long-struggling eye division, which investors expected would be spun off or sold next year. Not so, said CEO Joe Jimenez.
More: Novartis beats Q3 estimates but investors balk at plans to delay Alcon exit
Source: fierce